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ABSTRACT
Objectives: Neuregulin 4 (NRG4) is an adipokine that is synthesized in many tissues and has been shown to be associated 
with the development of obesity and metabolic disorders in animals and humans. The aim of this study is to investigate 
the relationship between serum NRG4 levels and various metabolic parameters in women with PCOS. 
Material and methods: This cross-sectional study included 40 women with PCOS and 40 age- and BMI-matched controls 
without PCOS. NRG4, fasting blood glucose (FBG), insulin, hs-CRP, LDL-C, HDL-C, SHBG, DHEA-SO4 and total-testosterone 
levels were measured in all the participants. HOMA-IR was used to calculate the insulin resistance. 
Results: Serum NRG4 levels were higher in women with PCOS than in healthy women (24.89 ± 9.32 [ng/mL] 
vs. 18.98 ± 6.40 [ng/mL], p = 0.002). FBG, LDL-C, HDL-C, LH, SHBG, FAI, DHEA-SO4, insulin, hs-CRP, HOMA-IR and total-tes-
tosterone levels were significantly higher in women with PCOS than controls. Circulating NRG4 levels were positively cor-
related with HOMA-IR, insulin and hs-CRP for both groups. There was a positive correlation between NRG4 and FBG in the 
PCOS group. HOMA-IR and hs-CRP were associated with NRG4. 
Conclusion: The high concentration of circulating NRG4 in PCOS may be associated with insulin resistance and low-grade 
chronic inflammation.
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INTRODUCTION
Polycystic ovarian syndrome (PCOS) is a common endo-
crinopathy affecting 5–10 percent of women during their re-
productive period and is characterized by ovulatory dysfunc-
tion, polycystic ovaries and biochemical (elevated androgens) 
and/or clinical (hirsutism, acne) hyperandrogenism. PCOS is 
a disease associated with insulin resistance, glucose intoler-
ance, metabolic syndrome, obesity, hyperlipidemia, hyperten-
sion, chronic low-grade inflammation and increased risk of 
developing type 2 diabetes mellitus (T2DM) [1–4]. Although 
the etiopathogenesis of PCOS is not yet fully understood, in-
sulin resistance and hyperinsulinemia play an important role 
in the etiopathogenesis of PCOS. In general, insulin resistance 
and hyperinsulinemia affect 70 percent of women with PCOS. 
Despite extensive research, the underlying mechanism of 
insulin resistance in PCOS has not been fully understood [5–8].
Neuregulin 4 (NRG4) is a member of the neuregulin pro-
tein family (NRG1-NRG4) and serves as an adipokine that is 
synthesized in many tissues, especially in brown adipose tissue 
(BAT). Similarly to other neuregulin members, NRG4 activates 
epidermal growth factor receptors (EGFR), also known as erbB 
receptors, and binds specifically to ErbB3 and ErbB4 receptors 
initiating cell-to-cell signaling via tyrosine phosphorylation 
[9, 10]. NRG4 has been shown to have an effect in the devel-
opment of obesity and metabolic disorders including T2DM 
and non-alcoholic fatty liver disease (NAFLD) in animals and 
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humans [11, 12]. NRG4 reduces hepatic lipogenic signals and 
it maintains glucose and lipid homeostasis in obesity [12]. 
NRG4 levels in humans have been correlated with body fat 
and liver fat mass and have been associated with increased 
insulin sensitivity and reduced hepatic steatosis when on 
high-fat diet compared to controls [12]. Also, a decreased 
NRG4 expression in BAT may be associated with obesity, 
glucose intolerance and insulin resistance [12, 13]. Yet, the 
role of NRG4 has not been fully understood in human homeo-
stasis. Despite many studies on T2DM, metabolic syndrome 
and NRG4, the relationship between NRG4 and PCOS has not 
been researched yet. For this reason, the aim of this study is 
to investigate the relationship between serum NRG4 levels 
and various metabolic parameters in patients with PCOS.
MATERIAL AND METHODS
This cross-sectional clinical trial study was conducted in 
Bursa Yuksek Ihtisas Training and Research Hospital Gynecol-
ogy and Obstetrics Clinic. The institutional ethical committee 
has approved the trial protocol. We enrolled in the study a total 
of 80 patients presenting to our gynecology outpatient clin-
ics. The study group composed of 40 women diagnosed with 
PCOS (age and BMI matched) while the control group consisted 
of age and BMI matched 40 women that had regular menstrual 
cycles. Detailed history of all patients was taken. After a physical 
exam we recorded anthropometric data (age, weight, height 
and waist circumference). Height [cm] and weight [kg] were 
measured with the patient barefoot in light daily clothes. BMI 
was calculated using the formula: weight [kg]/square meter 
of height [m2]. At the end of a gentle expiration, the waist cir-
cumference [cm] was measured at the level halfway between 
the lower rib and the iliac crest. Blood pressure was measured 
in the sitting position ensuring a min. of 15 [min] rest prior 
to measurement. The average of three measurements taken 
was calculated. The PCOS diagnosis was confirmed with at 
least two criteria according to the 2003 Rotterdam consen-
sus: oligo-ovulation or anovulation, presence of polycystic 
ovaries on transvaginal ultrasound and hyperandrogenism 
present as a laboratory finding and/or symptoms. According to 
a clinical Ferriman-Gallwey hyperandrogenism scoring system 
patients should have a minimum score of 8 and the biochemi-
cal hyperandrogenism was defined as total testosterone levels 
above the range that is regarded as normal (normal range: 
0.52–2.42 nmol/L) [14, 15]. For the evaluation of the polycystic 
ovaries’ (PCO) morphology, all women underwent transvaginal 
ultrasonography in the early follicular phase. The presence of 
PCO was diagnosed with the presence of 12 or more follicles 
with a diameter of 2–9 mm and/or increased ovarian volume 
(> 10 cm3) of each ovary. Menstrual periods were characterized 
by oligomenorrhea (absence of menstruation for 45 days or 
more) or by amenorrhea (no menstrual period for 3 months 
or more) in the PCOS group. The control group menstrual 
periods were regular and lasted 25–32 days. Additionally, 
the control group had neither hirsutism nor hyperandrogen-
ism. All participants were non-smokers and did not have any 
medical treatment in the past. Pregnant or lactating women, 
hyperprolactinemia, Cushing’s syndrome, congenital adrenal 
hyperplasia, other diseases of the adrenal gland, thyroid dis-
orders, impaired glucose tolerance, type 1 or type 2 diabetes 
mellitus and the use of insulin sensitizers or oral anti-diabetics 
were all excluded from the study.
Laboratory studies
Antecubital venous blood samples were taken from each 
female in the early follicular phase of menstruation (3rd to 
5th day). The samples were centrifuged and separated from 
the serum and stored at –80° C for analysis. High-density 
lipoprotein cholesterol (HDL-C), low-density lipoprotein cho-
lesterol (LDL-C), total testosterone, triglycerides, high-density 
lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), 
serum insulin, Dehydroepiandrosterone sulfate (DHEA-S), 
follicle stimulating hormone (FSH), luteinizing hormone (LH), 
estradiol (E2) and NRG4 levels were measured. FBG, serum 
hs-CRP, total cholesterol, total HDL-C and triglyceride levels 
were determined using an automated analyzer (Abbott Ar-
chitect C 16000, IL, USA) with its own kits (Abbott Diagnos-
tics, Wiesbaden, Germany). LDL-C was calculated using the 
Friedewald equation: LDL-C = total cholesterol- (HDL-C) – tri-
glyceride/5. Non-HDL-C was calculated as HDL-C subtracted 
from total cholesterol. Serum insulin levels were measured 
by an automated analyzer (Abbott Architect I2000, IL, USA) 
using a chemiluminescent microparticle immunoassay (CMIA) 
with its own kit (Abbott Diagnostics, Wiesbaden, Germany). 
Serum FSH, LH, E2, total testosterone and DHEA-S levels were 
measured with CMIA (Beckman Coulter Inc., Brea, CA, USA). 
Serum NRG4 concentrations were assessed by enzyme immu-
noassay (Elabscience, Wuhan, Hubei, China Catalog Number: 
E-EL-H0890). The intra-assay CV was < 10% and the inter-assay 
CV was < 12%. Using the formula stated for the homoeostasis 
model assessment of insulin resistance (HOMA-IR) method, 
the insulin resistance was calculated according to the formula: 
HOMA-IR = fasting insulin [mU/mL] × fasting glucose [mg/dL]/ 
/405 [16]. The free androgen index (FAI) was obtained as the 
quotient 100 testosterone/SHBG.
Statistical analysis
All statistical analysis was performed using the Statistical 
Package for the Social Sciences Software, version 18.0 (SPSS 
Inc., Chicago, IL. USA). The normality of the data was tested 
using the Kolmogorov-Smirnov test and all continuous vari-
ables had normal distribution (p > 0.05). Continuous variables 
were presented as mean ± standard deviation (SD). The de-
mographic and laboratory characteristics of women with and 
without PCOS were compared using the two-tailed independ-
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ent sample t-test. The relationship between NRG4 and other 
parameters was assessed by Pearson correlation analysis. To 
investigate the relationship between independent NRG4 lev-
els in PCOS development, multiple linear regression analyzes 
were performed to adjust for equivalence and to determine 
the independent relationships of NRG4 levels with age, BMI, 
HOMA-IR, FAI and hs-CRP. All independent variables in the 
multiple linear regressions were tested for multicollinearity. 
If the variance inflation factor (VIF) exceeded 2.5, the vari-
able was considered to be collinear. All reported confidence 
interval (CI) values are calculated at the 95% level. A two-sided 
p value of < 0.05 was considered statistically significant.
RESULTS
Clinical and laboratory characteristics  
of the study population
The comparative demographic and laboratory param-
eters of women with and without PCOS are presented in 
Table 1. The cases were matched in terms of age and BMI. 
Both parameters were similar and no statically significant 
differences were recorded between the groups (p > 0.05).
Serum NRG4 levels were higher in women with PCOS 
than in healthy women and the difference was statical-
ly significant (24.89 ± 9.32 ng/mL vs. 5.29 ± 1.45 ng/mL, 
p = 0.002). Serum FBG, LDL-C, HDL-C Triglyceride, LH, SHBG, 
FAI, DHEA-SO4, insulin, hs-CRP, HOMA-IR, total testoster-
one levels and Ferriman-Gallwey score were all significantly 
higher in women with PCOS than in healthy women.
Correlation analysis
Correlation was calculated between NRG4 and various 
other parameters in women with PCOS. Pearson’s correlation 
coefficients are presented in Table 2. Circulating NRG4 levels 
were positively correlated with HOMA-IR, insulin and hs-CRP 
in both groups. There was a positive correlation between 
NRG4 and FBG in the PCOS group.
Table 1. Comparison of demographic and laboratory characteristics of patients
Variables PCOS  n = 40
Controls
n = 40 P
a
Age (years)  27.54 ± 4.62  26.75 ± 4.73 0.453
BMI [kg/m2]  27.85 ± 4.37  27.57 ± 4.30 0.775
Waist circumference [cm]  88.20 ± 10.43  87.82 ± 10.01 0.546
SBP [mm Hg]  108.70 ± 12.63  107.93 ± 11.90 0.780
DBP [mm Hg]  74.82 ± 6.64  73.80 ± 5.77 0.465
Ferriman-Gallwey score  14.36 ± 3.25  4.13 ± 1.24 < 0.001*
FBG [mg/dL]  87.97 ± 6.69  82.72 ± 6.47 0.001*
Insulin [µIU/mL]  20.33 ± 6.45  11.77 ± 4.26 < 0.001*
HOMA-IR  4.40 ± 1.41  2.38 ± 0.83 < 0.001*
Total cholesterol [mg/dL]  221.90 ± 28.55  208.58 ± 41.33 0.098
LDL-C [mg/dL]  150.16 ± 24.53  135.00 ± 26.58 0.010*
HDL-C [mg/dL]  41.20 ± 8.57  50.65 ± 9.95 < 0.001*
Triglycerides [mg/dL]  152.68 ± 31.17  114.66 ± 27.45 < 0.001*
hs-CRP [mg/L]  1.41 ± 0.49  0.70 ± 0.18 < 0.001*
FSH [mIU/mL]  7.43 ± 1.63  7.47 ± 1.88 0.924
LH [mIU/mL]  12.88 ± 3.40  7.82 ± 2.68 < 0.001*
Estradiol [pg/mL]  54.56 ± 11.37  50.35 ± 7.33 0.053
Total-testosterone [nmol/L]  3.04 ± 0.39  1.74 ± 0.34 < 0.001*
SHBG [nmol/L]  41.03 ± 11.29  70.46 ± 13.86 < 0.001*
FAI (%)  7.80 ± 1.75  2.47 ± 0.09 < 0.001*
DHEA-SO4 [µg/dL]  195.55 ± 56.73  158.94 ± 36.47 0.001*
Neuregulin-4 [ng / mL]  24.89 ± 9.32  18.98 ± 6.40 0.002*
Results are given in mean ± SD. a Independent samples t-test was used. A P value of < 0.05 was considered significant*. BMI — body mass index; DHEA-S 
— dehydroepiandrosterone sulfate; DBP — diastolic blood pressure; FAI — free androgen index; FBG — fasting blood glucose; FSH — follicle-stimulating hormone; 
HDL-C — high density lipoprotein cholesterol; HOMA-IR — homeostasis model assessment of insulin resistance; hs-CRP — high sensitivity C-reactive protein; LDL-C 
— low density lipoprotein cholesterol; LH — luteinizing hormone; PCOS — polycystic ovary syndrome; SBP — systolic blood pressure; SHBG — sex hormone-binding 
globulin
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Multivariate regression analysis
A linear regression model was established using inde-
pendent variables that can influence the levels of NRG4, 
such as age, hs-CRP, HOMA-IR, BMI and FAI. According to 
this model HOMA-IR and Hs-CRP were associated with 
NRG4 levels (Tab. 3).
DISCUSSION
In this present study we have demonstrated for the first 
time that circulating NRG4 levels were significantly higher 
in women with PCOS when compared to control patients. In 
patients with PCOS NRG4 was positively correlated with 
insulin resistance marker HOMA-IR, inflammatory marker 
hs-CRP, insulin and with FBG. In addition, multivariate re-
gression analysis has shown that HOMA-IR and hs-CRP were 
both independent factors influencing serum NRG4 levels.
NRG4 is an adipokine that is similar to other neuregu-
lin family members. It activates epidermal growth factor 
receptor (EGFR), also known as erbB receptor, and is syn-
thesized in many tissues, especially in BAT [12, 17]. The 
hypothalamic-pituitary-gonadal axis and the luteinizing 
hormone-releasing hormone (LHRH) are required for healthy 
pubertal development [18, 19]. ErbB receptors have been 
shown to play an important role in the healthy functioning 
of LHRH. In mice with neuregulin-ErbB4/2 receptor defi-
ciency the required LHRH failed to be secreted so the sex 
development of mice was impaired [20]. Day et al. reported 
in their genetic study that ErbB2, ErbB3 and ErbB4 recep-
tors may be associated with PCOS [21]. In another animal 
study, overexpressed NRG4 has been shown to cause an in-
crease in insulin sensitivity while NRG4 deficiency has been 
shown to cause insulin resistance. Also, a different study on 
animals reports that NRG4 causes insulin secretion in Beta 
islet cells [12, 22]. Ma et al. report that NRG4 expressed in 
NRG4-transgenic mice was protective against insulin resist-
ance and obesity [23]. Although NRG4 is a novel adipokine 
and studies on humans have been limited, Cai et al. showed 
that circulating NRG4 levels in patients with metabolic syn-
drome were found to be lower than in control group. An in-
verse correlation was found between the level of NRG4 and 
the risk of metabolic syndrome with insulin resistance [24]. 
Jiang et al. reported that Serum NRG4 levels were associated 
with subclinical atherosclerosis in obese adults [25]. Kang 
et al. have found that there was no significant difference 
in the serum NRG4 levels when comparing type 2 diabetic 
patients with non-diabetic patients. Yet, there was a posi-
tive correlation between NRG4 levels and FBG, HOMA-IR 
and triglyceride levels [17]. In contrast, Zhang et al. have 
reported that type 2 diabetic patients were found to have 
Table 2. Correlation coefficients between neuregulin-4 levels and 
clinical parameters
Neuregulin-4
PCOS Control
r P r P
Age 0.156 0.327 0.243 0.264
BMI 0.163 0.478 0.257 0.268
Waist circumference 0.257 0.312 0.241 0.198
SBP 0.113 0.235 0.101 0.356
DBP 0.254 0.167 0.178 0.215
Insulin 0.298 0.017* 0.201 0.029*
FBG 0.135 0.046* 0.112 0.052
HOMA-IR 0.243 0.035* 0.125 0.041*
FAI 0.143 0.231 0.216 0.228
hs-CRP 0.326 0.007* 0.114 0.038*
Total cholesterol 0.264 0.167 0.124 0.127
LDL-C 0.312 0.169 0.278 0.431*
HDL-C 0.218 0.128 0.376 0.127
Triglycerides 0.271 0.472 0.367 0.145
Pearson’s correlation analysis was used. r — Pearson’s correlation 
coefficient; A P value of < 0.05 was considered significant (*). BMI — body 
mass index; DBP — diastolic blood pressure; FAI — free androgen index; 
FBG — fasting blood glucose; HDL-C — high-density lipoprotein cholesterol; 
HOMA-IR — homeostasis model assessment of insulin resistance; hs-CRP 
— high sensitivity C-reactive protein; LDL-C — low-density lipoprotein 
cholesterol; SBP — systolic blood pressure
Table 3. Evaluation of the association of Neuregulin-4 with age, BMI, HOMA-IR, FAI and Hs-CRP in the study population (women with and without 
PCOS) using multiple linear regression analysis
β 95% CI P
Variables Lower Upper
Age 0.685 –1.786 3.156 0.564
BMI 0.877 –0.781 2.542 0.327
HOMA-IR 3.234 1.684 4.785 0.014*
FAI 2.656 –2.584 7.896 0.276
hs-CRP 3.614 1.304 5.925 0.008*
Multiple linear regression analysis was used.β — Unstandardized regression coefficient; CI — confidence interval. A P value of < 0.05 was considered significant (*). 
BMI — body mass index; FAI — free androgen index; DBP — diastolic blood pressure; HOMA-IR — homeostasis model assessment of insulin resistance; hs-CRP — high 
sensitivity C-reactive protein
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a higher NRG4 level than the control group. Moreover, there 
was an inverse correlation between NRG4 levels and FBG, 
insulin and HOMA-IR [13]. Many studies in the literature 
show that NRG 4 indirectly affects the hormonal environ-
ment by binding to erbB receptors. In our study NRG4 level 
was significantly higher in patients with PCOS compared to 
control group. In addition, there was a positive correlation 
of circulating NRG4 level with HOMA-IR, insulin, FBG and 
hs-CRP. According to the multivariate regression analysis 
of our study, HOMA-IR and hs-CRP were associated with 
NRG4. We may hypothesize that there could be a problem 
in the interaction of NRG4 with erbB receptors in patients 
with PCOS and thus the high concentration of circulating 
NRG4 levels, which may be associated with insulin resist-
ance in PCOS.
PCOS is a low-grade chronic inflammatory disease. Many 
studies have shown a relationship between PCOS and in-
flammation markers [7, 8, 26]. There is also a relationship 
between NRG4 and chronic inflammatory state. Studies 
on animals with ulcerative colitis and Crohn’s disease have 
shown that NRG4 treated animals showed a decreased in-
flammation in the intestines and a decreased apoptosis in 
intestinal cells [27, 28]. Ma et al. report that NRG4-transgenic 
mice were found to have a decreased expression of mono-
cyte chemotactic protein 1 (Mcp1) and a decreased expres-
sion of macrophage-specific genes [19]. Similarly, our study 
has found that PCOS patients had higher levels of hs-CRP 
than controls. There was also a positive correlation between 
hs-CRP and NRG4 levels. Moreover, there was a significant re-
lationship between NRG4 and hs-CRP levels. Consequently, 
it may be that in patients with PCOS the NRG4 levels are in-
creasing as compensation mechanism to low-grade chronic 
inflammation during this disease.
In conclusion, NRG4 levels were found to be significantly 
higher in women with PCOS. There was also a significant 
correlation between HOMA-IR, hs-CRP and NRG4. Elevation 
of NRG4 levels in PCOS may be associated with increased 
insulin resistance and low-grade chronic inflammation. Our 
study is the first study in the literature to investigate such re-
lationship. More detailed studies are needed to understand 
the association and the role of NRG4 in PCOS.
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